Literature DB >> 10622167

Scintigraphic evaluation of dogs with acute synovitis after treatment with glucosamine hydrochloride and chondroitin sulfate.

S O Canapp1, R M McLaughlin, J J Hoskinson, J K Roush, M D Butine.   

Abstract

OBJECTIVE: To evaluate the effects of orally administered glucosamine hydrochloride (GlAm)-chondroitin sulfate (CS) and GlAm-CS-S-adenosyl-L-methionine (SAMe) on chemically induced synovitis in the radiocarpal joint of dogs. ANIMALS: 32 adult mixed-breed dogs. PROCEDURE: For 21 days, all dogs received a sham capsule (3 groups) or GlAm-CS (prior treatment group) in a double-blinded study. Unilateral carpal synovitis was induced by injecting the right radiocarpal joint with chymopapain and the left radiocarpal joint (control joint) with saline (0.9% NaCl) solution. Joints were injected on alternate days for 3 injections. After induction of synovitis, 2 groups receiving sham treatment were given GlAm-CS or GlAm-CS-SAMe. Another group continued to receive sham capsules (control group). Joint inflammation was quantified, using nuclear scintigraphy, before injection of joints and days 13, 20, 27, 34, 41, and 48 after injection. Lameness evaluations were performed daily.
RESULTS: Dogs given GlAm-CS before induction of synovitis had significantly less scintigraphic activity in the soft-tissue phase 48 days after joint injection, significantly less uptake in the bone phase 41 and 48 days after joint injection, and significantly lower lameness scores on days 12 to 19, 23, and 24 after injection, compared with other groups. CONCLUSIONS AND CLINICAL RELEVANCE: Analysis of results of this study suggest that prior treatment with GlAm-CS for 21 days had a protective effect against chemically induced synovitis and associated bone remodeling. Prior treatment with GlAm-CS also reduced lameness in dogs with induced synovitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10622167

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  8 in total

Review 1.  Immunological activity of chondroitin sulfate.

Authors:  Toshihiko Toida; Shinobu Sakai; Hiroshi Akiyama; Robert J Linhardt
Journal:  Adv Pharmacol       Date:  2006

2.  Tissue distribution of [14C]sucrose octasulfate following oral administration to rats.

Authors:  Linda M Hiebert; Sandra M Wice; Tidly Ping; Ronald E Hileman; Tfilay Polat; Robert J Linhardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

3.  Anti-Inflammatory Effect of Carprofen Is Enhanced by Avocado/Soybean Unsaponifiables, Glucosamine and Chondroitin Sulfate Combination in Chondrocyte Microcarrier Spinner Culture.

Authors:  Mark W Grzanna; Erica J Secor; Lowella V Fortuno; Angela Y Au; Carmelita G Frondoza
Journal:  Cartilage       Date:  2018-06-25       Impact factor: 4.634

Review 4.  Glucosamine and chondroitin use in canines for osteoarthritis: A review.

Authors:  Angel Bhathal; Meredith Spryszak; Christopher Louizos; Grace Frankel
Journal:  Open Vet J       Date:  2017-02-24

5.  Hematologic and serologic status of military working dogs given standard diet containing natural botanical supplements.

Authors:  Eunchae Lee; Jun-Ha Choi; Ha-Jeong Jeong; Sung-Gu Hwang; Sangrak Lee; Jae-Wook Oh
Journal:  Toxicol Rep       Date:  2018-03-08

Review 6.  Proposed Canadian Consensus Guidelines on Osteoarthritis Treatment Based on OA-COAST Stages 1-4.

Authors:  Conny Mosley; Tara Edwards; Laura Romano; Geoffrey Truchetti; Laurie Dunbar; Teresa Schiller; Tom Gibson; Charles Bruce; Eric Troncy
Journal:  Front Vet Sci       Date:  2022-04-26

7.  Collagen Synthesis in tenocytes, ligament cells and chondrocytes exposed to a combination of Glucosamine HCl and chondroitin sulfate.

Authors:  Louis Lippiello
Journal:  Evid Based Complement Alternat Med       Date:  2006-12-01       Impact factor: 2.629

8.  Glucosamine and chondroitin sulfate supplementation to treat symptomatic disc degeneration: biochemical rationale and case report.

Authors:  Wim J van Blitterswijk; Jos C M van de Nes; Paul I J M Wuisman
Journal:  BMC Complement Altern Med       Date:  2003-06-10       Impact factor: 3.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.